Nebimel (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors, decreasing heart rate and contractility, which lowers cardiac output. It also stimulates nitric‑oxide production in the endothelium, causing vasodilation and further reducing peripheral resistance and blood pressure.

The appropriate nebivolol dose is determined by the prescribing clinician based on the patient’s condition, response, and tolerability. Dosage may be adjusted during treatment, and patients should follow the exact regimen provided by their healthcare professional.

Nebivolol’s safety in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Nebimel, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nebivolol is distinguished by its β1‑selectivity and nitric‑oxide mediated vasodilation, which may result in fewer metabolic side effects compared with non‑selective beta‑blockers. Clinicians consider individual patient profiles, comorbidities, and tolerability when choosing between nebivolol and alternatives such as metoprolol or atenolol.

Nebimel tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Nebimel is taken orally, usually once daily with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe bradycardia, marked hypotension, heart block, bronchospasm in patients with reactive airway disease, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience symptoms like fainting, severe dizziness, or breathing difficulties.

Nebimel is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and individuals with uncompensated heart failure. Caution is also advised for patients with asthma, COPD, or significant hepatic impairment.